In Trading, Results Matter.
Our Top 10 exits in last 5 trading days.

Arrowhead Research Corp.. Trade Record

NASDAQ:ARWR Arrowhead Research Corp. stock gains 42.16% Exit Jun 7, 2018 a Trade Record by priceseries

Trade Chart
Trade Chart ARWR May 2, 2018, priceSeries
About Arrowhead Research Corp.

Arrowhead Pharmaceuticals, Inc. develops novel drugs to treat intractable diseases in the United States. Its pre-clinical stage drug candidates include ARO-HBV to treat chronic hepatitis B virus infection; ARO-AAT to treat liver disease associated with alpha-1 antitrypsin deficiency; ARO-LPA to reduce production of apolipoprotein A; ARO-AMG1, which is developed against an undisclosed genetically validated cardiovascular target; and ARO-F12, a potential treatment for factor 12 mediated diseases, such as hereditary angioedema and thromboembolic disorders. The company also develops ARO-HIF2, a drug candidate for the treatment of clear cell renal cell carcinoma. Arrowhead Pharmaceuticals, Inc. has collaboration and license agreements with Amgen, Inc. The company was formerly known as Arrowhead Research Corporation and changed its name to Arrowhead Pharmaceuticals, Inc. in April 2016. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.

Trade Information
Trade Type
LONG
ReliabilityScore™
94.85
Entry Date
May 2, 2018
Entry Price
7.14
Sell Date
Jun 7, 2018
Sell Price
10.15
Net Gain
42.16%
Hold Time
25 Trading Days